About 29,785 results

ALLMedicine™ Human Papillomavirus Center

Research & Reviews  10,329 results

Proportion of incident genital human papillomavirus detections not attributable to tran...
Clinical Infectious Diseases : an Official Publication Of... Malagón T, MacCosham A et. al.

Dec 2nd, 2021 - Infections with human papillomaviruses (HPV) may enter a latent state, and eventually become reactivated following loss of immune control. It is unclear what proportion of incident HPV detections are reactivations of previous latent infections ver...

Genetic variability of the HPV16 early genes and LCR. Present and future perspectives.
Expert Reviews in Molecular Medicine; Bletsa G, Zagouri F et. al.

Dec 2nd, 2021 - Human papillomavirus 16 (HPV16) infection is the aetiologic factor for the development of cervical dysplasia and is regarded as highly carcinogen, because it is implicated in more than 50% of cervical cancer cases, worldwide. The tumourigenic pote...

Real-world impact and effectiveness assessment of the quadrivalent HPV vaccine: a syste...
Expert Review of Vaccines; Wang W, Kothari S et. al.

Dec 1st, 2021 - Vaccine effectiveness and impact studies are typically observational, generating evidence after vaccine launch in a real-world setting. For human papillomavirus (HPV) vaccination studies, the variety of data sources and methods used is pronounced....

Promoting adolescent health through integrated human papillomavirus vaccination program...
Vaccine Engel D, Afeli ADJ et. al.

Dec 1st, 2021 - The introduction of the Human papillomavirus (HPV) vaccine has shown potential to not only prevent cervical cancer but also drive adolescents' access to other health care services, even in low-income countries. Few studies have been conducted to d...

Human papillomavirus-independent cervical cancer: what are the implications?
International Journal of Gynecological Cancer : Official ... Schmeler KM, Batman SH

Dec 1st, 2021 - Human papillomavirus-independent cervical cancer: what are the implications?|2021|Schmeler KM,Batman SH,|

see more →

Guidelines  42 results

ACR Appropriateness Criteria® Staging and Follow-up of Vulvar Cancer.
Journal of the American College of Radiology : JACR; , Lakhman Y et. al.

May 8th, 2021 - Vulvar cancer is an uncommon gynecologic tumor and one of several human papillomavirus-associated malignancies. Squamous cell carcinoma is the most prevalent histologic subtype of vulvar cancer, accounting for the majority of cases. Imaging plays ...

ASCCP Risk-Based Colposcopy Recommendations Applied in Thai Women With Atypical Squamou...
Obstetrics and Gynecology; Phianpiset R, Ruengkhachorn I et. al.

Aug 10th, 2020 - To compare the proportion of cervical intraepithelial neoplasia (CIN) 2 or worse pathology among different risk strata according to the ASCCP when applied in women who had atypical squamous cells of undetermined significance (ASC-US) or low-grade ...

Human Papillomavirus Vaccination: ACOG Committee Opinion, Number 809.
Obstetrics and Gynecology;

Aug 1st, 2020 - Human papillomavirus (HPV) causes significant morbidity and mortality in women and men. The HPV vaccine significantly reduces the incidence of anogenital cancer and genital warts in women and in men. Human papillomavirus vaccines are among the mos...

Cervical cancer screening for individuals at average risk: 2020 guideline update from t...
CA: a Cancer Journal for Clinicians; Fontham ETH, Wolf AMD et. al.

Jul 31st, 2020 - The American Cancer Society (ACS) recommends that individuals with a cervix initiate cervical cancer screening at age 25 years and undergo primary human papillomavirus (HPV) testing every 5 years through age 65 years (preferred); if primary HPV te...

Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideli...
CA: a Cancer Journal for Clinicians; Saslow D, Andrews KS et. al.

Jul 9th, 2020 - The American Cancer Society (ACS) presents an adaptation of the current Advisory Committee on Immunization Practices recommendations for human papillomavirus (HPV) vaccination. The ACS recommends routine HPV vaccination between ages 9 and 12 years...

see more →

Drugs  10 results see all →

Clinicaltrials.gov  238 results

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Nov 25th, 2021 - The primary objective of the study is to estimate the clinical benefit of cemiplimab + ISA101b after progression on first line chemotherapy, as assessed by objective response rate (ORR). The secondary objectives of the study are: To characterize t...

Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer

Nov 23rd, 2021 - Background: Patients with non-metastatic carcinoma of the anal canal are treated with concurrent mitomycin C (MMC), 5-fluorouracil (5-FU), and radiotherapy (RT) in the curative setting in an attempt to preserve the anal sphincter. Radiation dermat...

Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)

Nov 22nd, 2021 - This is a 96-month safety and immunogenicity study conducted in boys and girls 9 to 14 years of age and in young women 16 to 26 years of age. From this study, the goal is to establish that the investigational extended 2-dose regimens (0, 12 months...

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Nov 19th, 2021 - PRIMARY OBJECTIVES: I. To determine the immunogenicity of recombinant human papillomavirus nonavalent vaccine (GARDASIL 9) administered after allogeneic stem cell transplant (SCT) in patients with hematologic malignancy by comparing HPV 9-plex com...

A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer

Nov 16th, 2021 - The window of opportunity, Study H-200-002, will examine the effects of study agent (HB-201) on subjects during the "window" between diagnosis of their cancer and their definitive cancer surgery or chemoradiation. The study will be a 2-arm study d...

see more →

News  1,275 results

Success of HPV Vaccination: 'Dramatic' Reduction in Cervical Cancer

Nov 4th, 2021 - New data from England show the success of the national program for vaccinating girls against human papillomavirus (HPV) to prevent cervical cancer. Among young women who received the HPV vaccine when they were 12 or 13 years old (before their sexu...

Acyclovir-Resistant Cutaneous Herpes Simplex Virus in DOCK8 Deficiency
Christina R. Hopkins, MD, Nicholas Lowe, MD et. al.

Oct 12th, 2021 - Dedicator of cytokinesis 8 (DOCK8 ) deficiency is the major cause of autosomal-recessive hyper-IgEsyndrome. 1 Characteristic clinical features including eosinophilia, eczema, and recurrent Staphylococcus aureus cutaneous and respiratory tract infe.

HPV Vaccine Hesitancy Remains High Among US Parents

Oct 12th, 2021 - NEW YORK (Reuters Health) - Hesitancy over the human papillomavirus (HPV) vaccine remains high among parents in the United States, with almost two-thirds of parents on the fence about getting their child vaccinated, according to a new study. The H...

Study Adds Pembrolizumab to Paradigm for Certain Head and Neck Cancers

Oct 6th, 2021 - Ravindra Uppaluri, MD, PhD Associate Professor, Otolaryngology Washington University School of Medicine in St. Louis Surgeon, Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis St. ...

The HPV Puzzle: Quest to Deintensify Therapy in Oropharyngeal Cancer Continues

Oct 6th, 2021 - Nabil F. Saba, MD After more than 2 decades of change in the epidemiology of oropharyngeal cancers, the choice of optimal treatment for patients with human papillomavirus (HPV)—positive disease remains elusive. Investigators are testing strategie...

see more →

Patient Education  20 results see all →